Harlow S.D., Gass M., Hall J.E., et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012;15(2):105–114.
Hoffman B. Williams Gynecology. New York: McGraw-Hill Medical. 2012:555–56.
ESHRE Capri Workshop Group. Perimenopausal risk factors and future health. Human Reproduction Update. 2011;17(5):706–17.
Boardman H.M., Hartley L., Eisinga A., Main C., Roque i Figuls M., Bonfill Cosp X., Gabriel Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. The Cochrane Database of Systematic Reviews. 2015 Mar 10(3).
North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;(17):242–255.
Regidor P.A. Progesterone in Periand Postmenopause: A Review. Geburtshilfe Frauenheilkd. 2014;74(11):995–1002.
Сметник А.А. Менопаузальная гормонотерапия с дидрогестероном: аспекты эффективности и безопасности ультранизких доз. Медицинский совет. 2017;(2):92-99. doi: 10.21518/2079-701X-2017-2-92-99..
DOI: 10.21518/2079-701X-2017-2-92-99
Stevenson J.C., Durand G., Kahler E. et al. Oral ultralow dose continuous combined hormone replacement therapy with 0.5 mg 17betaoestradiol and 2.5 mgdydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas, 2010;(67):227–32.
Maki P.M., Drogos L.L., Rubin L.H., Banuvar S., Shulman L.P., Geller S.E. Objective hot flashes are negatively related to verbal memory performance in midlife women. Menopause. 2008 Sep-Oct;15(5):848-56.
Gambacciani M., Cappagli B., Ciaponi M., Pepe A., Vacca F., Genazzani A.R. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas. 2008;(59):2–6.
Stevenson J.C., Panay N., Pexman-Fieth C. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: Review of efficacy and safety. Maturitas. 2013;(760:10-21.
Schierbeck L.L., Rejnmark L., Tofteng C.L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. British Medical Journal. 2012;(345):e6409.
Anderson G.L., Chlebowski R.T., Aragaki A.K., et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended followup of the Women’s Health Initiative randomisedplacebocontrolled trial. The Lancet Oncology. 2012;(13):476–86.
Khalid Rida Murshid. A Review of Mastalgia in Patients with Fibrocystic Breast Changes and the Non-Surgical Treatment Options. Journal of Taibah University Medical Sciences. 2011;6(Issue 1):1-18.
Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;(107):103–111.
Schneider C., Jick S.S., Meier C.R. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacetric. 2009:1–11 ([Epub ahead of print]).
Bergeron C., Nogales F.F., Rechberger T. et al. Ultra low dose continuous combined hormone replacement therapy with 0.5 mg 17beta-oestradiol and 2,5 mg dydrogesterone: protection of the endometrium and amenorrhoea rate. Maturitas. 2010;66(2):201-205.